

CORRECTION

Correction: Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis

B Douglas Smith^{1†}, Charles L Beach², Dalia Mahmoud^{3†}, Laura Weber³ and Henry J Henk^{4*†}

After the publication of this work [1], it was brought to our attention that a statement in the article is not consistent with the data. The statement “Prior RBC transfusions were found to significantly increase the time to hospitalization (adjusted HR 1.373, $p = 0.018$) while no other covariates examined were found to impact the risk of hospitalization” is not a correct reflection of the results from the data analysis in Table 2 of the article.

The corrected statement is provided here as follows:

“Prior RBC transfusions were found to significantly shorten the time to hospitalization (adjusted HR 1.373, $p = 0.018$) while no other covariates examined were found to impact the risk of hospitalization.”

Author details

¹Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. ²Hematology/Oncology Clinical Research and Development, Celgene, Summit, NJ, USA. ³Global Pricing and Market Access, Celgene, Summit, NJ, USA. ⁴Health Economic and Outcomes Research, Optum, Eden Prairie, MN, USA.

Published: 16 July 2014

Reference

1. Smith DB, Beach CL, Mahmoud D, Weber L, Henk HJ: Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. *Exp Hematol Oncol* 2014, **3**:10.

doi:10.1186/2162-3619-3-19

Cite this article as: Smith et al.: Correction: Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. *Experimental Hematology & Oncology* 2014 **3**:19.

* Correspondence: Henry.Henk@optum.com

†Equal contributors

⁴Health Economic and Outcomes Research, Optum, Eden Prairie, MN, USA